
Please try another search
CAMBRIDGE - The European Commission has granted marketing authorization for Moderna's (NASDAQ:MRNA) updated COVID-19 vaccine Spikevax targeting the SARS-CoV-2 variant LP.8.1, the company announced...
Moderna Inc. (NASDAQ:MRNA) received marketing authorization from the European Commission for its updated COVID-19 vaccine Spikevax targeting the SARS-CoV-2 variant LP.8.1, the company...
Moderna Inc. (NASDAQ:MRNA) announced that three abstracts on its investigational mRNA cancer therapies have been accepted for presentation at the 2025 European Society for Medical Oncology...
Moderna , Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing...
Investing.com -- Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) stock rose 4.4% after the U.S. Food and Drug Administration (FDA) approved its COVID-19 vaccine, Spikevax, for children aged 6 months...
Investing.com - Brookline Capital Markets has reiterated a Buy rating on Moderna (NASDAQ:MRNA) with a price target of $198.00 following FDA approval of the company's COVID-19 vaccine for younger...
Moderna , Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Spikevax®, the Company's...
Investing.com -- Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna 's patents. A year...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review